
Loading, please wait...

Loading, please wait...

Researchers at the Indian Institute of Technology Bombay (IIT Bombay) have pioneered a novel antibiotic resistance strategy to combat the growing threat of superbugs. This method focuses on making drug-resistant bacteria responsive to existing medications again. Consequently, this approach bypasses the long and expensive process of discovering entirely new drug classes. The team, led by Prof Ruchi Anand and Prof P I Pradeepkumar, focuses on protecting current therapeutic resources rather than finding replacements.
Globally, antimicrobial resistance creates a massive burden on healthcare systems. Physicians routinely use antibiotics for pneumonia, tuberculosis, and surgical prophylaxis. However, the indiscriminate use of these drugs has rendered many common treatments ineffective. Therefore, the scientific community is looking for innovative ways to restore the efficacy of traditional treatments.
The first phase of the research involves the use of short, synthetic DNA sequences called aptamers. Specifically, these aptamers act as molecular decoys. They effectively block the enzymes that bacteria produce to neutralize antibiotics. Unlike many conventional drugs, aptamers consist of nucleic acids, making them relatively stable and easy to modify in a laboratory setting. Furthermore, synthetic production ensures a consistent quality for potential clinical applications.
Despite their high performance in laboratory assays, delivering these molecules into bacteria presents a significant challenge. Naked DNA molecules are prone to degradation by nucleases. Additionally, they often struggle to cross the complex bacterial membrane. To solve this, the researchers have turned to advanced delivery technologies to ensure the DNA reaches its target effectively.
To overcome delivery hurdles, the IIT Bombay team developed a liposome-based system. Liposomes are tiny spheres composed of fatty molecules that mimic biological cell membranes. Consequently, these vesicles protect the aptamers from external degradation and facilitate their entry into the bacterial cell. Prof Anand noted that synthesizing DNA is straightforward and liposome formulations are already common in modern medicine. This existing infrastructure could accelerate the transition from the laboratory to the clinic.
This antibiotic resistance strategy offers a promising path forward. By blocking resistance mechanisms, clinicians could potentially re-sensitize old antibiotics. While more research, including animal studies and pharmacokinetic analyses, remains necessary, the beauty of the approach lies in its practicality. Specifically, it allows the healthcare industry to maximize the utility of known drugs with established safety profiles.
Q1: How do DNA aptamers help fight antibiotic resistance?
Aptamers are short DNA sequences that bind to and block the specific enzymes bacteria use to resist antibiotics. By neutralizing these enzymes, the aptamers allow the original antibiotic to work effectively once again.
Q2: Why is a liposome-based delivery system necessary for this strategy?
Aptamers alone can be broken down by bacterial enzymes or fail to enter the cell. Liposomes act as protective bubbles that shield the DNA and help it cross the bacterial membrane to reach its target.
Q3: Can this method be used with any antibiotic?
The strategy is designed to be versatile. However, researchers must tailor the specific aptamer sequence to match the resistance mechanism of the target bacteria and the antibiotic being used.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


IIT Bombay researchers have developed a DNA-based strategy using aptamers to block resistance mechanisms, potentially making old antibiotics effective again...
5 months ago

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today